ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Our Board of Directors
The GTx Board is divided into three classes, designated as Class I, Class II and Class III. GTx's charter documents provide
that each class must consist, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. The staggered structure of the GTx Board will remain in place
following completion of the merger. Pursuant to the Merger Agreement, each of the directors and officers of GTx who will not continue as directors or officers of GTx or the surviving corporation
following the consummation of the merger will resign immediately prior to the Effective Time. Effective as of the Effective Time, it is anticipated that only Drs. Carter and Wills will remain on the
GTx Board.
The
following includes a brief biography of each current member of the GTx Board (including their respective ages as of March 31, 2019), with terms expiring as shown, with each
biography including information regarding the experiences, qualifications, attributes or skills that caused the Nominating and Corporate Governance Committee and the GTx Board to determine that the
applicable director should serve as a member of our Board of Directors.
Class III Directors Continuing in Office Until the 2019 Annual Meeting
Michael G. Carter, M.D., Ch.B., F.R.C.P.
Dr. Carter, age 81, was appointed as a director in May 2006 and currently serves as Chair of the Compensation Committee and as a member
of both the Audit Committee and the Scientific and Development Committee. Dr. Carter was a non-executive director of Santarus, Inc. from 2004 to 2013, served as a non-executive director
of Micromet AG from 2001 to 2005 and of MICROMET, Inc. from 2006 to March 2012, and served as a non-executive director of Fulcrum Pharma, PLC from 2005 to 2010. Dr. Carter was a
member of the Advisory Board of Paul Capital Royalty Fund from 2005 to 2008, and was a venture partner with SV Life Sciences Advisors, LLP from 1998 to 2016. He has served as a member of the
strategic advisory board of Healthcare Royalty Partners (HCRP) since September 2009 and a member of the HCRP Investment Committee since 2015. Dr. Carter was the non-executive chairman of Metris
Therapeutics, Ltd., a biotechnology firm specializing in women's healthcare from 1999 to 2008. He was also a non-executive director of ONCOETHIX from June 2013 until its sale to
Merck & Co., in December 2014. Dr. Carter served on the Pharmaceutical Board of I.C.I. Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions
with I.C.I. Zeneca from 1984 to 1998, including International Medical Director and International Marketing Director. From 1985 to 1995, Dr. Carter served as a member of the U.K. Government's
Medicines Commission. Dr. Carter is an Elected Fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh.
Dr. Carter holds a degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.). Dr. Carter brings to the GTx Board specific
expertise in the development and commercialization of pharmaceutical products by both large pharmaceutical companies and small specialty biotech companies.
2
Table of Contents
Mr. Hyde, age 76, has served as a director since November 2000, and currently serves as a member of the Compensation Committee and the
Nominating and Corporate Governance Committee. From November 2000 to March 2015, Mr. Hyde served as non-executive Chairman of our Board of Directors. In connection with Dr. Wills'
assumption of duties as our Executive Chairman in March 2015, Mr. Hyde was appointed as our Lead Director. Since 1989, Mr. Hyde has been the sole stockholder and President of Pittco
Holdings, Inc., a private institutional investment company. Since 1996, when Mr. Hyde made a substantial contribution to support the research of our prior CEO, Mr. Hyde has been
instrumental in forming and financing GTx and is our largest stockholder. Mr. Hyde was the Chairman of the Board of Directors of AutoZone, Inc. (NYSE: AZO) from 1986 to 1997 and the
Chief Executive Officer of AutoZone from 1986 to 1996. From March 2005 to June 2007, Mr. Hyde served as the non-executive chairman of the Board of Directors of AutoZone, Inc. He was also
Chairman and Chief Executive Officer of Malone & Hyde, Inc., AutoZone's former parent company, from 1972 until 1988. Mr. Hyde also served as a director of FedEx Corporation (NYSE:
FDX) from 1977 to 2011. As the largest stockholder of GTx and with a long history of serving as both Chairman and Chief Executive Officer of a large publicly-traded company and a member of the board
of directors of other public companies, Mr. Hyde has continued to serve as a principal architect of the GTx public company governance structure, and continues to be a primary advisor to senior
management on all matters of strategic importance. The GTx Board believes that Mr. Hyde's leadership role and public company experience, as well as his significant ownership interest in the
company, qualifies him to serve as the Lead Director of the GTx Board.
Class I Directors Continuing in Office Until the 2020 Annual Meeting
Mr. Hanover, age 56, a co-founder of GTx, served as our President and Chief Operating Officer from our inception in September 1997 until
his appointment as our permanent Chief Executive Officer in February 2015, and served as our acting Principal Financial Officer from December 31, 2013 until his appointment as our interim Chief
Executive Officer on April 3, 2014. He also previously served as a member of our Board of Directors from September 1997 to August 2011. Prior to joining GTx, Mr. Hanover was a founder of
Equity Partners International, Inc., a private equity firm in Memphis, Tennessee, and participated as a founder and investor in three healthcare companies. From 1985 to 1997, Mr. Hanover
was a Senior Vice President and a member of the Executive Management Committee of National Bank of Commerce in Memphis, Tennessee. Mr. Hanover holds a B.S. in Biology from the University of
Memphis and an MBA in Finance from the University of Memphis. Mr. Hanover serves as our Chief Executive Officer and he is responsible for overseeing all aspects of our business, including
product development and business strategies. Accordingly, the Nominating and Corporate Governance Committee and our Board of Directors has determined that Mr. Hanover should serve as a member
of our Board of Directors since he is best able to impart to our Board of Directors the business and financial acumen essential for a complete understanding by our Board of Directors of GTx's
operations, strategies and developmental plans.
3
Table of Contents
Dr. Neil, age 65, has served as a director since August 2016 and currently serves as a member of the Nominating and Corporate Governance
Committee and the Board's Scientific and Development Committee. Dr. Neil joined as CSO of Aevi Genomic Medicine in September 2013. Prior to joining Aevi Genomic Medicine, Dr. Neil held a
number of senior positions in the pharmaceutical industry, academia and venture capital. These include Corporate Vice President of Science & Technology at Johnson & Johnson and Group
President at Johnson & Johnson Pharmaceutical Research and Development, Vice President of Research and Development at Merck KGaA/EMD Pharmaceuticals, Vice President of Clinical Research at
Astra Zeneca and Astra Merck. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and
genitourinary and gastrointestinal diseases gained initial or expanded approvals. Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan
College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research
fellowship at the Research Institute of Scripps Clinic. He is the Founding Chairman of the Pharmaceutical Industry R&D Consortium, TransCelerate Biopharmaceuticals Inc., and remains on the
Board. He also serves on the Boards of Reagan Udall Foundation, GTx Pharmaceuticals, Arena Pharmaceuticals and is a past member of the Board of Foundation for the National Institutes of Health (FNIH),
and the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA
Foundation Board. The GTx Nominating and Corporate Governance Committee and the GTx Board finds Dr. Neil's experience and background in drug development and regulatory interactions helpful on
the GTx Board.
Kenneth S. Robinson, M.D., M.Div.
Dr. Robinson, age 64, has served as a director since May 2008 and currently serves as Chair of the Nominating and Corporate Governance
Committee and as a member of the Audit Committee. From 2003 through 2007, Dr. Robinson served in the cabinet of Tennessee Governor Phil Bredesen as Commissioner of Health, and in April 2009,
Dr. Robinson accepted an appointment to provide executive-level public health leadership and consultation as the Health Officer of Shelby County, Tennessee, the county in which GTx is located.
In February 2011, Dr. Robinson was appointed as Public Health Policy Advisor for Shelby County, Tennessee. From 1982 through 1991, Dr. Robinson taught and practiced internal medicine at
Vanderbilt University School of Medicine, and from 1991 through 2003, he was an Assistant Dean at the University of Tennessee College of Medicine. Since 2015, he has served as President and CEO of
United Way of the Mid-South. Dr. Robinson holds a B.A., cum laude, from Harvard University, a M.D. from Harvard Medical School, and a Master of Divinity from Vanderbilt Divinity School. As a
Harvard-trained physician who has experience in overseeing the complexities of federal and state agencies' provision of healthcare to elderly and indigent patients, Dr. Robinson brings to the
GTx Board expertise in governance, governmental reimbursement related issues, population health data and priorities, and the role of government in the development and delivery of healthcare services.
Dr. Robinson, an African-American, adds an element of racial balance to the GTx Board and also provides a voice for GTx with state and local officials.
4
Table of Contents
Class II Directors Continuing in Office Until the 2021 Annual Meeting
Mr. Glass, age 72, has served as a director since March 2004, and currently serves as the Chair of the Audit Committee and also currently
serves on the Compensation Committee. Mr. Glass retired as Chairman of the Board, President and Chief Executive Officer of First Horizon National Corporation (NYSE: FHN), or First Horizon, as
of January 29, 2007. Mr. Glass was named President and Chief Executive Officer of First Horizon in July 2002, and he also became First Horizon's Chairman of the Board in January 2004.
From 2003 through 2007, Mr. Glass served as a director of FedEx Corporation (NYSE: FDX). From July 2001 through July 2002, Mr. Glass was President and Chief Operating Officer of First
Horizon. From 1993 to 2001, Mr. Glass was Business Unit President of First Tennessee Bank. Mr. Glass received his B.A. in Accounting from Harding University and graduated from Harvard
Business School's Advanced Management Program. With his background in accounting and as a Chief Executive Officer, Mr. Glass serves in the role of a financial expert for our Audit Committee,
and his years of experience leading a publicly-owned bank holding company has provided him with the organizational skills, risk management expertise and leadership he currently brings to the GTx Board
and the Audit Committee.
Dr. Wills, age 65, has over three decades of experience as a leader in the pharmaceutical and biotechnology industry. Dr. Wills
joined GTx as the Executive Chairman of the Board of Directors and as Chairman of the Board's Scientific and Development Committee on March 2, 2015. He also serves as Chairman of the Board of
CymaBay Therapeutics, as board member at Parion Sciences, Inc., as board member at Go Therapeutics and as a member of the Emerging Companies Section Governing Board of Biotechnology Innovation
Organization (BIO). Prior to these roles, Dr. Wills spent over 25 years at Johnson & Johnson. Most recently he was Vice President, Alliance Management, Janssen Pharmaceutical
Companies of Johnson & Johnson. He also served as Senior Vice President Global Development where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition,
he served on several of the commercial Operating Company Boards key pharmaceutical group decision-making committees. Dr. Wills began his career at Hoffmann-LaRoche where he spent
10 years in several roles of scientific responsibility. He holds a BS in Biochemistry and an MS in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the
University of Texas.
Our Executive Officers
The following table sets forth information about our executive officers as of March 31, 2019:
|
|
|
|
|
Name
|
|
Age
|
|
Position(s)
|
Marc S. Hanover
|
|
56
|
|
Chief Executive Officer
|
Robert J. Wills, Ph.D
|
|
65
|
|
Executive Chairman
|
Henry P. Doggrell
|
|
70
|
|
Vice President, Chief Legal Officer and Secretary
|
Jason T. Shackelford
|
|
43
|
|
Vice President, Finance and Accounting, and Principal Financial and Accounting Officer
|
The
biographies of Marc S. Hanover and Robert J. Wills, Ph.D. are provided above under the subsection "
Our Board of Directors."
5
Table of Contents
Henry P. Doggrell
currently serves as GTx's Vice President, Chief Legal Officer and Secretary, after joining GTx in October 2001 as
General Counsel and Secretary. From April 1998 to August 2001, Mr. Doggrell was Senior Vice President, Corporate Affairs at Buckeye Technologies, Inc., a specialty cellulose company,
where he was responsible for matters including corporate finance, investor relations, mergers and acquisitions, intellectual property and licensing and strategic development. From 1996 to 1998,
Mr. Doggrell served as General Counsel and Secretary of Buckeye Technologies. Prior to joining Buckeye Technologies, Mr. Doggrell was a partner of the Baker, Donelson, Bearman, Caldwell
and Berkowitz law firm from 1988 to 1996, where he served as a member of the law firm management committee and Chair of the firm's Corporate Securities department. Mr. Doggrell holds a B.S. in
Commerce from the University of Virginia and a JD from Vanderbilt University.
Jason T. Shackelford
currently serves as GTx's Vice President, Finance and Accounting, after joining GTx in July 2007 as Director,
Accounting and Corporate Controller, and has served as our principal accounting officer since December 31, 2013 and as our principal financial and accounting officer since April 3, 2014.
Prior to joining GTx, Mr. Shackelford was a Senior Audit Manager at KPMG LLP. Mr. Shackelford is a Certified Public Accountant and holds a Bachelor of Business Administration and
Master of Accountancy from the University of Mississippi.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our executive officers and directors and the beneficial owners of greater than 10% of our
common stock to file initial reports of ownership and reports of changes in ownership with the SEC. Executive officers and directors are required by SEC regulations to furnish us with copies of these
reports.
To
our knowledge, based solely on a review of the copies of these reports furnished to us and any written representations from such executive officers, directors and stockholders with
respect to the period from January 1, 2018 through December 31, 2018, all Section 16(a) filing requirements applicable to our officers, directors and greater than ten percent
beneficial owners were complied with.
Copies
of filings made by our executive officers, directors and stockholders under Section 16(a) of the Exchange Act can be found at our corporate website at
www.gtxinc.com
under "Investors" at "SEC
Filings."
Certain Corporate Governance Matters
Our Audit Committee.
We have a standing Audit Committee that is currently composed of three directors: J. Kenneth Glass (Chair),
Michael G. Carter
and Kenneth S. Robinson. The GTx Board has determined that the members of the Audit Committee are independent under applicable Nasdaq listing standards and SEC rules. In addition, the GTx Board has
determined that Mr. Glass, the Chair of the Audit Committee, qualifies as an "audit committee financial expert" within the meaning of the SEC rules.
Code of Ethics.
The GTx Board has adopted a Code of Business Conduct and Ethics applicable to all officers, directors and employees as
well as
Guidelines on Governance Issues. These documents are available on our website (
www.gtxinc.com
) under "Investors" at "Corporate Governance." We will
provide a copy of these documents to any person, without charge, upon request, by writing to us at GTx, Inc., Chief Legal Officer, 17 W Pontotoc Ave., Suite 100, Memphis, Tennessee
38103. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the Code of Business Conduct and Ethics by
posting such information on our website at the address and the location specified above.
Director Nominations.
No material changes have been made to the procedures by which stockholders may recommend nominees to the GTx
Board.
6
Table of Contents
ITEM 11. EXECUTIVE COMPENSATION
Summary Compensation Table
The following table sets forth certain summary information for the years indicated with respect to the compensation earned by our Chief
Executive Officer and our two most highly compensated executive officers other than our Chief Executive Officer who were serving as executive officers as of December 31, 2018. We refer to these
individuals in this report as our "named executive officers."
SUMMARY COMPENSATION TABLE
FISCAL 2018 AND 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
Salary
($)
(1)
|
|
Bonus
($)
(2)
|
|
Option
Awards
($)
(3)
|
|
Non-Equity
Incentive
Plan
Compensation
($)
(4)
|
|
All Other
Compensation
($)
(5)
|
|
Total
($)
|
|
Marc S. Hanover
|
|
|
2018
|
|
|
445,628
|
|
|
|
|
|
659,984
|
|
|
115,863
|
|
|
22,338
|
|
|
1,243,813
|
|
Chief Executive Officer
|
|
|
2017
|
|
|
432,649
|
|
|
28,122
|
|
|
346,988
|
|
|
154,672
|
|
|
21,586
|
|
|
984,017
|
|
Robert J. Wills
|
|
|
2018
|
|
|
226,600
|
|
|
|
|
|
659,984
|
|
|
58,916
|
|
|
36,046
|
|
|
981,546
|
|
Executive Chairman
|
|
|
2017
|
|
|
220,000
|
|
|
14,300
|
|
|
346,988
|
|
|
78,650
|
|
|
31,268
|
|
|
691,206
|
|
Henry P. Doggrell
|
|
|
2018
|
|
|
389,463
|
|
|
|
|
|
456,912
|
|
|
54,525
|
|
|
24,836
|
|
|
925,736
|
|
Vice President, Chief Legal Officer
|
|
|
2017
|
|
|
378,119
|
|
|
13,234
|
|
|
292,200
|
|
|
72,788
|
|
|
21,996
|
|
|
778,337
|
|
and Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
(1)
-
The
amounts in this column represent base salary earned during the indicated fiscal year.
-
(2)
-
The
amounts in this column represent amounts awarded as a discretionary bonus paid under our Executive Bonus Compensation Plan, or the Bonus Plan. As discussed under
"
Narrative Disclosure to Summary Compensation Table Annual Bonus Plan
" below, each named executive officer was eligible
for a discretionary bonus award of up to 10% of his target bonus under the Bonus Plan based on the GTx Compensation Committee's assessment of the named executive officer's personal performance during
2017 and 2018. No discretionary bonuses were awarded for 2018 performance.
-
(3)
-
The
amounts in the column represent the aggregate grant date fair value of all option awards granted during 2017 and 2018 as determined in accordance with FASB ASC
Topic 718. Assumptions used in computing the grant date fair values of the stock options in accordance with FASB ASC Topic 718 are set forth in Note 3 Share-Based
Compensation to our audited financial statements included in the 2018 10-K. For more information on these stock options granted in 2017 and 2018, see "
Narrative
Disclosure to Summary Compensation Table Option Awards
" below.
-
(4)
-
Represents
the amounts earned by the named executive officers under the Bonus Plan based on the attainment of pre-established, objective performance goals approved
by the Compensation Committee. For more information on our Bonus Plan, please see "
Narrative Disclosure to Summary Compensation Table Annual
Bonus Plan
" below.
-
(5)
-
The
amounts in this column consisted of (a) employer matching contributions to our defined contribution 401(k) Plan, (b) with respect to
Mr. Hanover and Mr. Doggrell only, the incremental cost of life insurance premiums to provide additional term life insurance benefits equal to up to two times each such named executive
officer's base salary along with supplemental long-term disability insurance premiums, and (c) with respect to Dr. Wills only, the following items of
compensation:
|
|
|
|
|
|
|
|
Year
|
|
Commuting
Expenses Paid
($)
|
|
Tax Gross-Up
Payment
($)
|
|
2018
|
|
|
17,350
|
|
|
9,038
|
|
2017
|
|
|
11,820
|
|
|
8,648
|
|
7
Table of Contents
Narrative Disclosure to Summary Compensation Table
Base Salary
Our Compensation Committee recognizes the importance of base salary as an element of compensation that helps to attract and retain our executive
officers. We provide base salary as a fixed source of income for our executives for the services they provide to us during the year, and allow us to maintain a stable executive team.
In
determining base salaries for 2018, the Compensation Committee took into account that there had been no salary increases since 2016 other than in connection with certain employee
promotions. After considering GTx's capital position and the achievement of certain operational milestones during 2017, in November 2017, the Compensation Committee determined that the base salaries
of our executive officers and other employees should be increased approximately 3% from their existing base salaries, effective January 1, 2018. The Compensation Committee also approved the
performance criteria for 2018 under our Bonus Plan that were tied to the attainment of certain milestones, as described in detail below. Additionally, the base salaries of our named executive officers
were increased, effective January 1, 2018, to the following:
|
|
|
|
|
Named Executive Officer
|
|
2018 Annual Base Salary
($)
|
|
Marc S. Hanover
|
|
|
445,628
|
|
Robert J. Wills, Ph.D.
|
|
|
226,600
|
(1)
|
Henry P. Doggrell
|
|
|
389,463
|
|
-
(1)
-
Dr. Wills'
base salary reflects his agreement with us to work part time but to make himself available at all other times as may be required.
Following
the results of our placebo-controlled Phase 2 clinical trial of enobosarm to evaluate the change in frequency of daily stress urinary incontinence, or SUI, episodes
following 12 weeks of treatment, or the ASTRID trial, the Compensation Committee did not adjust any base salaries for 2019, and determined to maintain existing executive base salary levels at
the beginning of 2019 at the same levels that existed in 2018.
Annual Bonus Plan
General.
Our Compensation Committee first established our Bonus Plan in 2007 as a means of rewarding executive officers for their role
in achieving
specified annual or short-term performance goals. The potential for payments under the Bonus Plan for any fiscal year is generally based on the attainment of pre-established, objective performance
goals approved by the Compensation Committee at the beginning of the year. Each year, unless cash bonus award eligibility under the Bonus Plan is suspended or eliminated for the relevant year, the
Compensation Committee approves the objective performance goals and specific criteria, including the weight attributable to each objective, and, if applicable, any weighting for specific categories of
performance objectives, for each executive officer. The Compensation Committee (as it did for bonus eligibility under the Bonus Plan for 2018) may include a subjective, discretionary bonus payment
opportunity based on the Compensation Committee's assessment of the executive officer's personal performance. Historically, the Compensation Committee solicits and considers the recommendations of our
senior management officers in making these determinations.
8
Table of Contents
The
objective criteria for the Bonus Plan can vary each year and may include the achievement of the operating budget for GTx, personnel-related objectives, continued innovation in
development and progress towards the clinical development of our product candidates, timely development of new product candidates or processes, implementation of financing strategies, including
licensing and/or asset dispositions that raise near-term capital for GTx and provide opportunities for increased stockholder value, the establishment of strategic alliances, partnerships or
collaborations with third parties, and meeting preclinical, clinical, or regulatory objectives.
Although
the Compensation Committee typically approves the performance goals and specific criteria prior to the start of or early in the applicable calendar year, it retains the
discretion to modify or otherwise change the objectives during the applicable calendar year. In addition, under the Bonus Plan, the Compensation Committee has the discretion to make additional bonus
awards, apart from those related to the achievement of specified performance objectives.
Bonus Plan for 2018.
In December 2017, our Compensation Committee initially approved the performance criteria to be achieved in order
for our
executive officers to be eligible to receive cash bonus awards under the Bonus Plan for the performance period from January 1, 2018 through December 31, 2018. In March 2018, the
Compensation Committee revised the performance criteria to allocate most of the cash bonus award potential to the attainment of enrollment goals in the ASTRID trial within a designated time period,
and to the achievement of certain clinical results in the ASTRID trial. For 2018, an executive officer could have received: (i) 40% of such executive officer's target bonus as a result of the
achievement of enrollment goals in the ASTRID trial within a designated time period; (ii) 50% of such executive officer's target bonus as a result of the achievement of certain clinical results
in the ASTRID trial; and (iii) 10% of such executive officer's target bonus related to certain pre-clinical goals related to our SARD technology. However, in the event that a strategic
transaction resulted in the cancelation or modification of any of the milestone events set forth above prior to their anticipated occurrence, any such milestone events that had been canceled or
modified would have been deemed to have been fulfilled and the commensurate bonus payment or payments associated with such milestone events would have become payable. Additionally, an executive
officer was eligible for a bonus award of up to 10% of his or her target bonus based on the Compensation Committee's assessment of the executive officer's personal performance. Accordingly, an
executive officer's actual total bonus award could have been awarded at a level above target. As in 2017, the potential bonus payments under the Bonus Plan for 2018 were 65% of base salary for
Mr. Hanover and Dr. Wills and 35% of base salary for the other executive officers of the Company. Also as in 2017, actual cash bonus awards under the Bonus Plan for 2018 generally were
paid upon the achievement of the applicable performance criteria.
Fiscal Year 2018 Payouts.
A bonus payment equal to approximately 40% of each named executive officer's target bonus payment was paid in
April 2018
following the achievement of the enrollment goals in the ASTRID trial. No other bonus payments tied to the objective performance criteria for 2018 were earned by the named executive officers, and no
discretionary bonus payments were awarded to our named executive officers. Below is a summary of each named executive officer's target bonus and actual bonus for 2018 under the Bonus Plan:
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year 2018 Bonus Plan Results
|
|
Named Executive Officer
|
|
Total Target
Award
($)
|
|
Target
Percentage
(% of Base
Salary)
|
|
Total Amount
Actually Awarded
($)
|
|
Marc S. Hanover
|
|
|
289,658
|
|
|
65
|
|
|
115,863
|
|
Robert J. Wills, Ph.D.
|
|
|
147,290
|
|
|
65
|
|
|
58,916
|
|
Henry P. Doggrell
|
|
|
136,212
|
|
|
35
|
|
|
54,525
|
|
9
Table of Contents
Bonus Plan for 2019.
Following the results from the ASTRID trial, the Compensation Committee determined that the executive's focus
should be on
developing strategies for the GTx Board's consideration to maximize stockholder value, given the diminished prospects for the Company, including partnering, collaborating or selling the Company's
remaining assets or selling or merging the Company with interested third parties. The Compensation Committee felt that it was not appropriate to develop a Bonus Plan for 2019 that would reward
executives for attaining any specific goals since trying to formulate a plan to realize stockholder value was deemed paramount, even if it meant that some or all company employees may lose their
employment depending on the strategies the GTx Board decided to adopt.
Option Awards
Option Awards for 2018.
In December 2017, the Compensation Committee approved the grant of stock options to purchase 65,000 shares of
GTx common
stock to each of Mr. Hanover and Dr. Wills, and a stock option to purchase 45,000 shares of GTx common stock to Mr. Doggrell, each of which grants was effective on
January 1, 2018. The stock options vest in three equal annual installments beginning January 1, 2021, subject to continuous service, thus providing long term incentive compensation for
those employees who remain with GTx and increase stockholder value. The exercise price for these stock options is $12.71 per share, the closing price of GTx's common stock on December 29, 2017,
the last trading day of 2017. The stock options expire on December 31, 2027, unless they are forfeited or expire earlier in accordance with their terms.
Option Awards for 2019.
There were no stock options awarded to company employees as of January 1, 2019, due to the results of the
ASTRID
trial.
General Provisions of Stock Option Awards.
All options granted to our named executive officers may be exercised with cash, provided
that the GTx
Board or the Compensation Committee may provide that the exercise price may also be paid by delivery to us of other unencumbered shares of our common stock with a value equal to the aggregate option
exercise price, pursuant to a cashless exercise program, or in any other form of legal consideration that may be acceptable to the GTx Board or the Compensation Committee (which may include a "net
exercise" of the option). As a general matter, the vested portion of the stock options granted to our named executive officers in 2018 and in previous years will expire three months after the named
executive officer's last day of service with us, subject to extension in certain termination situations as described below under "
Post-Termination
Compensation Stock Option and Equity Plan Provisions Extended Post-Termination Option Exercise Period
" below. Events that can
accelerate the vesting of GTx's stock options are described below under "
Post-Termination Compensation Stock Option and Equity Plan
Provisions Stock Award Vesting Acceleration
" below.
Employment Agreements
Each of our named executive officers has entered into a written employment agreement with GTx. Descriptions of our employment agreements with
our named executive officers are included under the caption "
Post-Termination Compensation Employment
Agreement
s" below.
10
Table of Contents
Other Compensatory Arrangements
For a description of the other elements of our executive compensation program, see "
Post-Termination
Compensation Retirement and Other Benefits
." Except for the benefits described under "
Post-Termination
Compensation Retirement and Other Benefits
," GTx does not generally provide its executive officers with any other perquisites and benefits that differ from
what are provided to GTx employees generally. To date, the Compensation Committee has not generally considered the provision of such additional perquisites and benefits to be a necessary element of
GTx's executive compensation program. However, GTx may, from time to time, offer certain perquisites and benefits to its executive officers not offered to the general employee population, such as
commuting, relocation and temporary housing benefits. In this regard, we reimbursed travel-related expenses for Dr. Wills in 2018 for travel between his out-of-state permanent residence and
GTx's headquarters in Memphis, Tennessee. Upon the recommendation of the Compensation Committee, the GTx Board also approved tax gross-up payments to Dr. Wills related to these expense
reimbursements, as the reimbursements are taxable to Dr. Wills as imputed income. The Compensation Committee believes that the provision of tax gross-up payments to Dr. Wills to offset
the tax obligation associated with these imputed income amounts was appropriate and necessary for retaining Dr. Wills.
Outstanding Equity Awards at Fiscal-Year End
The following table summarizes the number of outstanding equity awards held by each of our named executive officers as of December 31,
2018. There were no stock awards outstanding as of December 31, 2018.
11
Table of Contents
OUTSTANDING EQUITY AWARDS AT 2018 FISCAL-YEAR END
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Number of Securities
Underlying Unexercised
Options (#)
|
|
Number of Securities
Underlying Unexercised
Options (#)
|
|
|
|
|
|
|
Option Exercise
Price ($)
|
|
Option Expiration
Date
|
Name
|
|
Exercisable
|
|
Unexercisable
(1)
|
Marc S. Hanover
|
|
|
7,000
|
|
|
|
|
|
42.00
|
|
12/31/19
|
|
|
|
7,000
|
|
|
|
|
|
26.50
|
|
12/31/20
|
|
|
|
7,000
|
|
|
|
|
|
33.60
|
|
12/31/21
|
|
|
|
9,000
|
|
|
|
|
|
42.00
|
|
12/31/22
|
|
|
|
40,000
|
|
|
10,000
|
(2)
|
|
15.60
|
|
04/02/24
|
|
|
|
16,667
|
|
|
8,333
|
(3)
|
|
13.30
|
|
06/04/24
|
|
|
|
|
|
|
40,000
|
(4)
|
|
7.00
|
|
12/31/25
|
|
|
|
|
|
|
95,000
|
(5)
|
|
4.71
|
|
02/27/27
|
|
|
|
|
|
|
65,000
|
(6)
|
|
12.71
|
|
12/31/27
|
Robert J. Wills
|
|
|
|
|
|
40,000
|
(4)
|
|
7.00
|
|
12/31/25
|
|
|
|
|
|
|
95,000
|
(5)
|
|
4.71
|
|
02/27/27
|
|
|
|
|
|
|
65,000
|
(6)
|
|
12.71
|
|
12/31/27
|
Henry P. Doggrell
|
|
|
3,500
|
|
|
|
|
|
42.00
|
|
12/31/19
|
|
|
|
3,500
|
|
|
|
|
|
26.50
|
|
12/31/20
|
|
|
|
3,500
|
|
|
|
|
|
33.60
|
|
12/31/21
|
|
|
|
5,500
|
|
|
|
|
|
42.00
|
|
12/31/22
|
|
|
|
10,000
|
|
|
|
|
|
18.80
|
|
09/30/23
|
|
|
|
13,334
|
|
|
6,666
|
(3)
|
|
13.30
|
|
06/04/24
|
|
|
|
|
|
|
25,000
|
(4)
|
|
7.00
|
|
12/31/25
|
|
|
|
|
|
|
80,000
|
(5)
|
|
4.71
|
|
02/27/27
|
|
|
|
|
|
|
45,000
|
(6)
|
|
12.71
|
|
12/31/27
|
-
(1)
-
All
options have a term of ten years from the date of grant. In addition to the specific vesting schedule for each stock option, each unvested stock option is
subject potential future vesting acceleration as described under the heading "
Post-Termination Compensation
" below. Pursuant to the
Merger Agreement, all of these options will vest immediately prior to the consummation of the merger.
-
(2)
-
One-fifth
of the shares subject to the option vested on each of April 3, 2015, April 2, 2016, April 3, 2017 and April 3, 2018, with the
remaining shares vesting as to one-fifth of the shares on April 3, 2019.
-
(3)
-
One-third
of the shares subject to the option vested on each of June 5, 2017 and June 5, 2018, with the remaining shares vesting as to one-third of the
shares on June 5, 2019.
-
(4)
-
One-third
of the shares subject to the option vested on January 1, 2019, with the remaining shares vesting as to one-third of the shares on each of
January 1, 2020 and January 1, 2021.
-
(5)
-
One-third
of the shares subject to the option will vest on each of February 28, 2020, February 28, 2021 and February 28, 2022.
-
(6)
-
One-third
of the shares subject to the option will vest on each of January 1, 2021, January 1, 2022 and January 1, 2023.
12
Table of Contents
Option Exercises and Stock Vested During 2018
The following table provides information on restricted stock unit, or RSU, awards vested and the value realized, determined as described below,
for the named executive officers during the year ended December 31, 2018. No stock options were exercised by the named executive officers during the year ended December 31, 2018.
|
|
|
|
|
|
|
|
|
|
Stock Awards
|
|
Name
|
|
Number of Shares
Acquired on Vesting
(#)
|
|
Value Realized
on Vesting
($)
(1)
|
|
Marc S. Hanover
|
|
|
45,000
|
|
|
571,950
|
|
Robert J. Wills
|
|
|
33,333
|
|
|
560,328
|
|
Henry P. Doggrell
|
|
|
30,000
|
|
|
381,300
|
|
-
(1)
-
The
value realized on vesting is based on the number of shares underlying the RSU awards that vested and the closing price of our common stock on the vesting date
(or, in the case of RSU awards vesting on a day that was not a trading day, the closing price of our common stock on the immediately preceding trading day).
Post-Termination Compensation
We have entered into employment agreements with each of our named executive officers. Described below are the circumstances that would trigger
our obligation to make cash payments pursuant to these employment agreements following the termination of a named executive officer's employment with us and the cash payments that we would be required
to provide. We also describe below the termination and change of control events that would trigger the accelerated vesting of stock options and the extension of the post-termination exercise period
with respect to those stock options.
Employment Agreements
The employment agreements with our named executive officers provide for cash post-termination change of control payments equal to one year's
base salary and, for those executives eligible for COBRA under federal law, monthly premium payments to continue the named executive officer's health insurance coverage for up to 12 months
following his or her termination. These change of control salary continuation and health insurance coverage benefits are structured on a "double-trigger" basis, meaning that before a named executive
officer is eligible to receive such change of control benefits, (1) a change of control must occur and (2) within 12 months after such change of control, the named executive
officer's employment must be terminated without "cause" or the named executive officer must resign for "good reason." GTx's obligation to make the salary continuation payments and health insurance
premium payments under the employment agreements is conditioned upon the former named executive officer's compliance with the confidentiality provisions of the employment agreement and the provisions
of the non-competition provisions of the employment agreement for a period of one year following termination. In addition, GTx's obligation to make the salary continuation payments and health
insurance premium payments is conditioned upon GTx's receipt of an effective general release of claims executed by the named executive officer. The post-termination salary continuation payments will
either be made over the one-year period following termination on our regular payroll dates or in a lump sum, except that the timing of the monthly payments may be deferred for up to six months if
those payments would constitute deferred compensation under Section 409A of the Internal Revenue Code (in which case, the deferred payment would be made in a lump sum following the end of the
deferral period, with the balance being paid thereafter on our regular payroll dates).
13
Table of Contents
A
change of control generally means the following:
-
-
the sale or other disposition of all or substantially all of GTx's assets (including a liquidation or dissolution of GTx);
-
-
if any person or group acquires beneficial ownership of 50% or more of GTx's voting securities (subject to certain exceptions);
-
-
a merger or consolidation of GTx with or into any other entity, if immediately after the transaction more than 50% of the voting stock of the
surviving entity is held by persons who were not holders of at least 50% of GTx's voting stock as of the effective date of the named executive officer's employment agreement; or
-
-
a majority of our Board becomes comprised of individuals whose nomination, appointment, or election was not approved by a majority of the Board
members or their approved successors.
"
Cause
" is generally defined as the named executive officer's:
-
-
conviction for a felony;
-
-
theft, embezzlement, misappropriation of or intentional infliction of material damage to GTx's property or business opportunities;
-
-
breach of his or her confidentiality or non-competition obligations, as applicable, under his or her employment agreement; or
-
-
ongoing willful neglect of or failure to perform his or her duties, or his or her ongoing willful failure or refusal to follow any reasonable,
unambiguous duly adopted written direction that is not inconsistent with the description of such named executive officer's duties, provided that such willful neglect or failure is materially damaging
or materially detrimental to the business and operations of GTx, and after 30 days' notice and the opportunity to cure.
"
Good reason
" is generally defined as the following actions taken without the consent of the named executive officer after a change of
control (in each case where the named executive officer has provided written notice within 30 days of the action, such action is not remedied by GTx within 30 days following such notice,
and the named executive officer's resignation is effective not later than 60 days after the expiration of such 30-day cure):
-
-
an adverse change in the named executive officer's authority, duties or responsibilities (including reporting responsibilities) which, without
the named executive officer's consent, represents a material reduction in or a material demotion of the named executive officer's authority, duties or responsibilities as in effect immediately prior
to the change of control, or the assignment to the named executive officer of any duties or responsibilities that are materially inconsistent with and materially adverse to such authority, duties or
responsibilities;
-
-
a material reduction in the then current base salary of the named executive officer;
-
-
the relocation of the named executive officer's principal office to a location that increases his one-way commute by more than 20 miles (or, in
the case of Dr. Wills, a relocation outside of New Jersey);
14
Table of Contents
-
-
the failure of GTx to obtain an agreement reasonably satisfactory to the named executive officer from any successor entity upon the change of
control to assume and agree to perform his or her employment agreement in all material respects; or
-
-
a material breach by GTx of any provision of the named executive officer's employment agreement or any other then-effective agreement with the
named executive officer.
Termination Without "Cause" or For "Good Reason" Prior to or Not in Connection with a Change of Control
Our employment agreement with Dr. Wills provides for cash post-termination payments equal to one year's base salary (either to be made
over the one-year period following termination on our regular payroll dates or in a lump sum payment) and monthly premium payments to continue his health insurance coverage for up to 12 months
following his termination, should his employment be terminated without "cause" or should he resign for "good reason", in each case irrespective of whether such termination is within 12 months
after (or otherwise in connection with) a change of control.
If
we terminate a named executive officer's employment for "cause," or if a named executive officer voluntarily terminates his or her employment without "good reason," or upon the death
of a named executive officer, the named executive officer would generally have no right to receive any compensation or benefits under his or her employment agreement on or after the effective date of
termination, other than any accrued and unpaid salary and expense reimbursement. However, under our employment agreements with Dr. Wills, Dr. Wills would nonetheless be entitled to any
earned but unpaid annual bonus with respect to any completed calendar year immediately preceding his termination date. Likewise, except as described above under "
Termination Without "Cause" or For "Good Reason" Prior to or Not in Connection with a Change of Control
" with respect to Dr. Wills, if we terminate a named executive
officer's employment without "cause," or if a named executive officer voluntarily terminates his or her employment with "good reason," in each case not within 12 months following a change of
control, the named executive officer would have no right to receive any compensation or benefits under his employment agreement on or after the effective date of termination, other than any accrued
and unpaid salary and expense reimbursement and, solely in the case of Dr. Wills, subject to our obligation under his employment agreement to pay any accrued but unpaid annual bonus with
respect to any completed calendar year immediately preceding his termination date.
Except as set forth above, under the employment agreements with our named executive officers, our named executive officers would not be entitled
to any other benefits following termination of service, including the continuation of general employee benefits, life insurance coverage and long term disability coverage, except as otherwise required
by applicable law.
Stock Option and Equity Plan Provisions
Under the Merger Agreement, as of immediately prior to the Effective Time, the vesting of all outstanding options to purchase shares of our
common stock, including those held by our executive officers and directors, will accelerate in full. The number of shares of our common stock underlying such options and the exercise price of such
options will be adjusted appropriately to reflect the reverse stock split of GTx's common stock to be implemented prior to the consummation of the merger as set forth in the Merger Agreement.
15
Table of Contents
The
terms of our equity plans provide for additional accelerated exercisability that could apply in other scenarios, as described below.
2004 Plan.
Our 2004 Equity Incentive Plan, or the 2004 Plan, provides that in the event of a specified corporate transaction such as a
merger,
consolidation or similar transaction, all outstanding options under the 2004 Plan may be assumed, continued or substituted for by any surviving or acquiring entity. If the surviving or acquiring
entity elects not to assume, continue or substitute for such options, such options then held by individuals whose service has not terminated prior to the effective date of the corporate transaction
would become fully vested, and, if applicable, exercisable and such options would be terminated if not exercised within 90 days of the effective date of the corporate transaction. A recipient's
award agreement may provide for acceleration upon other events. In this regard, the standard form of stock option agreement under the 2004 Plan provides for each stock option to become fully vested
and exercisable if (i) the optionholder's service with GTx or its successor terminates within 12 months after a change of control and the termination of service is a result of an
involuntary termination without cause or a constructive termination or (ii) the optionholder is required to resign his or her position with GTx as a condition of the change of control. For
purposes of our 2004 Plan, the definition of change of control is similar to the definition of change of control under the employment agreements with our named executive officers. As a result of the
adoption of the 2013 Plan, we no longer grant any equity awards under the 2004 Plan, and stock options were the only form of stock awards granted to our named executive officers under the 2004 Plan.
The
standard form of stock option agreement under the 2004 Plan generally defines "cause" as the grant recipient:
-
-
committing an act that materially injures the business of GTx;
-
-
refusing or failing to follow the lawful and reasonable directions of the Board or the appropriate individual to whom he or she reports, after
15 days' notice and the opportunity to cure;
-
-
willfully or habitually neglecting his or her duties with GTx, after 15 days' notice and the opportunity to cure;
-
-
being convicted of a felony that is likely to inflict or has inflicted material injury on the business of GTx; or
-
-
committing a material fraud, misappropriation, embezzlement or other act of gross dishonesty that resulted in material loss, damage or injury
to GTx.
The
standard form of stock option agreement under the 2004 Plan generally defines a "constructive termination" as a voluntary termination within 12 months after a change of
control after any of the following actions are taken without the consent of the grant recipient:
-
-
the assignment to the grant recipient of any duties or responsibilities which results in a significant reduction in his or her function as in
effect immediately prior to the change of control;
-
-
a material reduction in the grant recipient's salary, as in effect on the effective date of the change of control;
16
Table of Contents
-
-
the failure to continue in effect any benefit plan or program in which the grant recipient was participating immediately prior to the effective
date of the change of control, or the taking of any action that would adversely affect his or her participation in (or reduce his or her benefits under) any such benefit plan or program (but either
circumstance will only be grounds for a "constructive termination" if the range of benefit plans and programs offered by the acquirer is not comparable to the benefit plans previously offered by GTx,
when considered as a whole);
-
-
a relocation of the grant recipient's principal office to a location more than 50 miles from the location at which he or she performed his or
her duties as of the effective date of the change of control; or
-
-
a material breach by GTx of any provision of the grant recipient's stock option agreement under the 2004 Plan.
2013 Plan.
Our 2013 Plan provides that in the event of a specified corporate transaction such as a merger, consolidation or similar
transaction, all
outstanding stock awards under the 2013 Plan may be assumed, continued or substituted for by any surviving or acquiring entity, and any reacquisition or repurchase rights held by GTx in respect of
common stock issued pursuant to outstanding stock awards may be assigned by GTx to its successor (or the successor's parent company). If the surviving or acquiring corporation does not assume,
continue or substitute any or all such outstanding stock awards, then with respect to stock awards that have not been assumed, continued or substituted and that are held by participants whose
continuous service has not terminated prior to the effective time of the corporate transaction, the vesting (and, if applicable, the exercisability) of such stock awards will (contingent upon the
effectiveness of the corporate transaction) be accelerated in full to a date prior to the effective time of the corporate transaction as the Board determines (or, if the Board does not determine such
a date, to the date that is five days prior to the effective time of the corporate transaction), such stock awards will terminate if not exercised (if applicable)at or prior to the effective time of
the corporate transaction, and any reacquisition or repurchase rights held by GTx with respect to such stock awards will (contingent upon the effectiveness of the corporate transaction) lapse. Unless
otherwise provided in a written agreement between GTx or an affiliate and a participant, the vesting (and, if applicable, the exercisability) of any other outstanding stock awards that are not
assumed, continued or substituted in connection with the corporate transaction will not be accelerated and such stock awards will terminate if not exercised (if applicable) prior to the effective time
of the corporate transaction. A recipient's award agreement may provide for acceleration upon other events. In this regard, the standard form of stock option agreement under the 2013 Plan provides for
each stock option to become fully vested and exercisable if the optionholder's service with GTx or its successor terminates on or within 12 months after a change of control and the termination
of service is a result of an involuntary termination without cause or a constructive termination. In addition, if a stock option is assumed, continued or substituted for in a change in control and a
participant's service terminates as a condition to such change in control or upon the effectiveness of the change in control, such stock option would remain exercisable for 12 months
post-termination.
For
purposes of our 2013 Plan, the definition of change of control is similar to the definition of change of control under the employment agreements with our named executive officers.
For
purposes of our 2013 Plan, "cause" has the meaning ascribed to such term in any written agreement between the grant recipient and GTx, and in the absence of such an agreement,
"cause" means the occurrence of any of the following:
-
-
the grant recipient's willful failure substantially to perform his or her duties and responsibilities or deliberate violation of a company
policy;
17
Table of Contents
-
-
the grant recipient's commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably
expected to result in material injury to GTx;
-
-
unauthorized use or disclosure by the grant recipient of any proprietary information or trade secrets of GTx or any affiliate or any other
party to whom the grant recipient owes an obligation of nondisclosure as a result of the grant recipient's relationship with GTx or any affiliate; or
-
-
the grant recipient's willful breach of any of his or her obligations under any written agreement or covenant with GTx or any affiliate.
The
definition of a "constructive termination" in the standard form of stock option agreement under the 2013 Plan is similar to the definition of a "constructive termination" in the
standard form of stock option agreement under the 2004 Plan, except that a constructive termination would also be deemed to occur if the board of GTx's successor requires the participant to resign
from GTx in a manner that terminates the participant's continuous service, as a condition of the change in control. In addition, in order to have a basis for constructive termination under the 2013
Plan, a participant must provide written notice of the event giving rise to constructive termination to the board of GTx's successor within 30 days following such event, provide the successor
with 30 days to cure such event, and, if not cured, the participant must resign from all positions then held with GTx and its successor not later than six months after the date of the
participant's written notice to the board of the successor (or such earlier date as may be requested by the Board).
As a general matter, the terms of the options we have granted to our executive officers provided that the vested portion of these options will
expire three months after the executive officer's termination of service. The period following the executive officer's termination during which he or she can continue to exercise his or her vested
stock options is referred to as the post-termination exercise period. However, in connection with the adoption of a retention bonus program by the Compensation Committee in September 2013, the options
held by certain of our executive officers and outstanding on or prior to September 27, 2013 were modified to generally provide for a six month post-termination exercise period. In addition, a
retention stock option granted to Mr. Doggrell in 2013 generally provides for a six month post-termination exercise period. All such post-termination exercise periods are limited by, and will
not exceed, the original expiration date of the option. The terms of the retention benefit agreements with our executive officers will, however, be less favorable than the terms for an extension of
the post-termination exercise period provided under the terms of our equity plans. Such more favorable terms will apply under the circumstances described below. Under our 2004 Plan and the form of
stock option agreement under our 2004 Plan, the post-termination exercise period will generally be one year following termination if the termination of service is a result of an involuntary
termination without cause or a constructive termination within 12 months after a change of control. Under our 2013 Plan and the form of stock option agreement under our 2013 Plan, the
post-termination exercise period will generally be one year following termination if the termination of service occurs either as a condition of a change of control or upon the effectiveness of a
change of control, unless the stock option is not assumed, continued or replaced by the successor or acquiring entity. If the termination is a retirement, the exercise period will be two years under
each of the 2004 Plan and 2013 Plan. Currently, Messrs. Hanover and Doggrell are retirement-eligible.
18
Table of Contents
With
respect to all of our stock option plans and the forms of stock option agreements under such stock option plans, if the termination is due to the named executive officer's death,
the post-termination exercise period will generally be 18 months following termination, and if the termination is due to the named executive officer's disability, the post-termination exercise
period will generally be one year following termination. With respect to our 2013 Plan and the form of stock option agreement under our 2013 Plan, if the termination is for cause, the option will
terminate upon the date on which the event giving rise to the termination for cause first occurred (or, if required by law, the date of the termination). With respect to our 2001 Plan and 2002 Plan
and the forms of stock option agreements under those plans, if a named executive officer voluntarily retires his or her employment (which generally means a retirement after age 65 or after age 55
following a specified period of service), the post-termination exercise period will generally be five years following termination. However, our 1999 and 2000 Plans provide that the Compensation
Committee in its discretion can provide for any post-termination exercise period for a vested option in the event of the disability, death or involuntary termination of an option grant recipient of up
to, but not exceeding, the initial ten-year term of the option. Under our 2004 Plan and 2013 Plan and the forms of stock option agreements under those plans, if a named executive officer voluntarily
retires his or her employment (which generally means a retirement after age 65 following a specified period of service or after age 55 following a specified period of service and with the
authorization of our Chief Executive Officer or the Board), the post-termination exercise period will generally be two years following termination. Currently, Messrs. Hanover and Doggrell are
retirement-eligible. In no event, however, will the post-termination exercise period be extended beyond the initial ten-year term of the option.
The
standard form of stock option agreement under the 2004 Plan generally defines "cause" as the grant recipient:
-
-
committing an act that materially injures the business of GTx;
-
-
refusing or failing to follow the lawful and reasonable directions of the Board or the appropriate individual to whom he or she reports, after
15 days' notice and the opportunity to cure;
-
-
willfully or habitually neglecting his or her duties with GTx, after 15 days' notice and the opportunity to cure;
-
-
being convicted of a felony that is likely to inflict or has inflicted material injury on the business of GTx; or
-
-
committing a material fraud, misappropriation, embezzlement or other act of gross dishonesty that resulted in material loss, damage or injury
to GTx.
The
standard form of stock option agreement under the 2004 Plan generally defines a "constructive termination" as a voluntary termination within 12 months after a change of
control after any of the following actions are taken without the consent of the grant recipient:
-
-
the assignment to the grant recipient of any duties or responsibilities which results in a significant reduction in his or her function as in
effect immediately prior to the change of control;
-
-
a material reduction in the grant recipient's salary, as in effect on the effective date of the change of control;
19
Table of Contents
-
-
the failure to continue in effect any benefit plan or program in which the grant recipient was participating immediately prior to the effective
date of the change of control, or the taking of any action that would adversely affect his or her participation in (or reduce his or her benefits under) any such benefit plan or program (but either
circumstance will only be grounds for a "constructive termination" if the range of benefit plans and programs offered by the acquirer is not comparable to the benefit plans previously offered by GTx,
when considered as a whole);
-
-
a relocation of the grant recipient's principal office to a location more than 50 miles from the location at which he or she performed his or
her duties as of the effective date of the change of control; or
-
-
a material breach by GTx of any provision of the grant recipient's stock option agreement under the 2004 Plan.
Retirement and Other Benefits
We do not provide our employees, including our named executive officers, with a defined benefit pension plan, any supplemental executive
retirement plans or retiree health benefits. Our named executive officers may participate on the same basis as other employees in our 401(k) retirement savings plan. Our 401(k) retirement savings plan
provides an employer matching contribution of 100% of the first 4% of the employee's eligible compensation, subject to the annual Internal Revenue Service limits in effect from time to time. We
believe this matching contribution is consistent with market practice and helps in attracting and retaining key executives. The 401(k) plan will be terminated prior to the closing of the merger.
We
offer a comprehensive employee benefit program, including health, life and disability insurance, to all of our regular employees, including certain of our named executive officers who
are full time employees. This program provides a safety net of protection against the financial catastrophes that can result from illness, disability or death. Company-funded life insurance of up to
$50,000 is provided to employees generally, and company-funded long-term disability insurance provides a 60% income-replacement benefit, up to $10,000 per month.
The
Compensation Committee has also approved supplemental life and long-term disability insurance for our executive officers. The total life insurance benefit for Mr. Hanover and
certain eligible Vice Presidents is equal to twice the executive officer's annual salary, not to exceed $1 million in coverage for any officer, although Mr. Doggrell's total coverage
amount was reduced 65% following his 65th birthday. Dr. Wills, as a part time employee, does not quality for health, life or disability insurance and other similar benefits pursuant to
the requirements of the insurers' programs. However, should he in the future be deemed to be a "full time" employee by the insurers, he would also receive the same benefits as are presently provided
to Mr. Hanover and our eligible Vice Presidents. The Compensation Committee believes that the cost of providing this supplemental insurance coverage is minimal in comparison to the value of
such benefits in attracting and retaining executive employees and that providing these supplemental benefits is consistent with the practices of other public companies.
20
Table of Contents
Compensation and Risk
In March 2018, the Compensation Committee considered our compensation policies, practices and programs as generally applicable to our employees
and determined that our policies, practices and programs do not encourage excessive or unnecessary risk-taking, and that the level of risk that they do encourage is not reasonably likely to have a
material adverse effect on our company. The design of our compensation policies and programs encourage our employees to remain focused on our long-term goals of increasing stockholder value through
the successful development of our clinical product candidates. For example, through our use of different types of equity compensation awards that provide long term incentives to increase our share
price, as well as our use of multi-year vesting for stock option, we believe that our employee compensation programs promote a long-term stockholder perspective, encourage decisions that will result
in sustainable performance over the longer term, and mitigate the risks associated with an undue short-term focus on results.
DIRECTOR COMPENSATION
Cash Retainers
The GTx Board has approved the GTx Non-Employee Director Compensation Policy, or the Director Compensation Policy, pursuant to which the
following cash compensation payments are made quarterly to the GTx Board and committee members:
-
-
a $35,000 annual retainer for service as a member of our Board of Directors;
-
-
a supplemental annual retainer for the Lead Director of the Board and for the Chairs of each Board committee in the following amounts: $15,000
for the Lead Director of the Board; $17,500 for Chair of the Audit Committee; $10,000 for Chair of the Compensation Committee; and $8,500 for Chair of the Nominating and Corporate Governance
Committee; and
-
-
a supplemental annual retainer for each member of the following committees other than the Chairs, in the following amounts: $10,000 for members
of the Audit Committee; $7,500 for members of the Compensation Committee; $5,000 for members of the Nominating & Corporate Governance Committee; and $10,000 for members of the Scientific and
Development Committee.
No
directors currently receive consulting fees from GTx. Directors who are also employees (currently Mr. Hanover and Dr. Wills) receive no additional compensation for
service on the GTx Board.
21
Table of Contents
Directors' Deferred Compensation Plan
Since June 30, 2004, our non-employee directors have had the opportunity to defer all or a portion of their fees under our Directors'
Deferred Compensation Plan. Deferrals can be made into a cash account, a stock account, or a combination of both. Deferrals into a cash account would accrue interest at the prime rate of interest
announced from time to time by a local bank utilized by us, and deferrals into a stock account accrue to the deferring director rights in shares of GTx common stock equal to the cash compensation then
payable to the director for his or her Board service divided by the then current fair market value of GTx common stock, or the Deferred Stock Rights. As of March 31, 2019, five of our
non-employee directors held Deferred Stock Rights, and an aggregate of 155,426 shares of our common stock were issuable pursuant to Deferred Stock Rights. In addition, as of March 31, 2019, two
of our non-employee directors had elected to defer compensation under the Director Deferred Compensation Plan after January 3, 2019, which deferrals will be paid to the non-employee directors
at the closing of the merger in cash. Under the Directors' Deferred Compensation Plan, amounts credited to cash or stock accounts are distributed in a single lump sum on the date, if any, selected by
the director pursuant to his or her election or, if no such election is made or if the selected distribution date is after his or her separation from service, then the distribution would be made on
the date of his or her separation from service in the form of a single lump sum (subject to deferral under certain circumstances to the extent necessary to avoid the incurrence of adverse personal tax
consequences under Section 409A of the Internal Revenue Code). Any fractional shares of GTx common stock will be distributed in cash valued at the then current fair market value of GTx common
stock.
Under
the Merger Agreement, as of immediately prior to the Effective Time (but in no event more than 30 days prior to the Effective Time), we shall take all actions necessary to
cause the termination and liquidation of the Deferred Stock Rights. As a result, the outstanding Deferred Stock Rights will be settled at the closing of the merger in shares, to the extent shares have
been credited to non-employee director stock accounts under the plan. We shall also ensure that any deferrals under the Director Deferred Compensation Plan on or after January 3, 2019 shall be
settled only in cash and that the maximum number of shares of our common stock issuable upon settlement of the Deferred Stock Rights shall be limited to the number of Deferred Stock Rights outstanding
as of the date of the Merger Agreement.
Equity Compensation
Pursuant to our Director Compensation Policy, each non-employee director of GTx (who does not own more than ten percent of the combined voting
power of GTx's then outstanding securities) is eligible for certain initial and annual stock awards, which grants are currently made pursuant to GTx's 2013 Non-Employee Director Equity Incentive Plan,
or the 2013 Directors' Plan. Accordingly, each of our non-employee directors, with the exception of Mr. Hyde, is eligible to receive these initial and annual non-statutory stock awards. Under
the Director Compensation Policy, any individual who first becomes a non-employee director is eligible for a stock award in such form and in such amount that the GTx Board deems necessary to attract
such individual to join the GTx Board. In addition, under the Director Compensation Policy, any individual who is serving as a non-employee director on the day following an annual meeting of GTx's
stockholders automatically will be granted an option to purchase shares of common stock on that date; provided, however, that if the individual has not been serving as a non-employee director for the
entire period since the preceding annual meeting, the number of shares subject to such individual's annual grant will be reduced pro rata for each full month prior to the date of grant during which
such individual did not serve as a non-employee director. In March 2018, the GTx Board, upon the upon the recommendations of the Nominating and Corporate Governance Committee and the Compensation
Committee, determined that the number of shares subject to the automatic annual grants occurring on the date following the 2018 Annual Meeting will be 7,500 shares of GTx common stock; accordingly,
each non-employee director then serving as a non-employee director received a grant for 7,500 shares on the date following the 2018 annual meeting of stockholders. Following the results from the
ASTRID trial, the GTx Board made no determination about stock option grants for Board members in 2019.
22
Table of Contents
The
shares subject to each initial grant and each annual grant vest in a series of three successive equal annual installments measured from the date of grant, so that each initial grant
and each annual grant will be fully vested three years after the date of grant. The exercise price per share for the options granted under the 2013 Directors' Plan is not less than the fair market
value of the stock on the date of grant. Prior to the adoption of the 2013 Directors' Plan at the 2013 annual meeting of stockholders, initial and annual stock option grants were made pursuant to the
Prior Directors' Plan.
In
the event of a specified corporate transaction, as defined in the Prior Directors' Plan or the 2013 Directors' Plan, as applicable, all outstanding options granted under the Prior
Directors' Plan and the 2013 Directors' Plan may be assumed or substituted for by any surviving or acquiring entity. If the surviving or acquiring entity elects not to assume or substitute for such
options, then (a) with respect to any such options that are held by optionees then performing services for GTx or its affiliates, the vesting and exercisability of such options will be
accelerated in full and such options will be terminated if not exercised prior to the effective date of the corporate transaction, and (b) all other outstanding options will terminate if not
exercised prior to the effective date of the corporate transaction. If a specified change of control transaction occurs, as defined in the Prior Directors' Plan, then the vesting and exercisability of
the optionee's options granted under the Prior Directors' Plan will be accelerated in full immediately prior to (and contingent upon) the effectiveness of the transaction. Under the Prior Directors'
Plan, if an optionee is required to resign his or her position as a non-employee director as a condition of the change of control transaction, the vesting and exercisability of the optionee's options
will be accelerated in full immediately prior to the effectiveness of such resignation. Under the 2013 Directors' Plan, if a specified change of control transaction occurs, as defined in the 2013
Directors' Plan, then all stock awards held by a participant whose continuous service has not terminated prior to such time will become fully vested and, if applicable, exercisable, immediately prior
to the transaction. In addition, under the 2013 Directors' Plan, if a non-employee director is required to resign his or her position as a non-employee director as a condition of the change of control
transaction, all outstanding stock awards held by such individual will become fully vested and, if applicable, exercisable, as of immediately prior to such resignation. During 2008, the GTx Board,
upon the recommendation of the Compensation Committee, adopted a general policy regarding the retirement of non-employee directors that provides that the GTx Board will act, on a case-by-case basis,
to accelerate the vesting and exercisability of the retiring director's options in full provided such director retires from the GTx Board in good standing.
Pursuant
to the merger agreement, all outstanding unvested options held by GTx's non-employee directors will vest upon the closing of the merger.
The
table below represents the compensation earned by each non-employee director who served on the GTx Board during 2018. Neither Mr. Hanover nor Dr. Wills are listed in
the following table since they served as our employees during their respective term service on our Board of Directors and did not receive any additional compensation for serving as members of our
Board of Directors. Each of Mr. Hanover's and Dr. Wills' compensation is described under "
Executive Compensation
" above.
DIRECTOR COMPENSATION FISCAL 2018
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Fees Earned or Paid
in Cash
($)
(1)
|
|
Option
Awards
($)
(2)
|
|
Total
($)
|
|
J. R. Hyde, III
|
|
|
62,500
|
|
|
|
|
|
62,500
|
|
Michael G. Carter, M.D.
|
|
|
65,000
|
|
|
99,197
|
|
|
164,197
|
|
J. Kenneth Glass
|
|
|
60,000
|
|
|
99,197
|
|
|
159,197
|
|
Garry A. Neil, M.D.
|
|
|
50,000
|
|
|
99,197
|
|
|
149,197
|
|
Kenneth S. Robinson, M.D., M.Div.
|
|
|
53,500
|
|
|
99,197
|
|
|
152,697
|
|
23
Table of Contents
-
(1)
-
Represents
fees earned in 2018 that were either paid, deferred or were payable at the end of 2018. Each director in the table above, other than Mr. Glass and
Dr. Carter elected to defer payment of all or a portion of his earned fees during 2018 pursuant to the Directors' Deferred Compensation Plan. The number of shares credited to individual stock
accounts for the GTx non-employee directors under the Directors' Deferred Compensation Plan as of December 31, 2018 was as follows: 52,108 shares for Mr. Hyde; 3,631 shares for
Dr. Carter; 655 shares for Mr. Glass; 22,224 shares for Dr. Neil and 44,105 shares for Dr. Robinson.
-
(2)
-
The
amounts in this column represent the aggregate grant date fair value of all option awards granted to our non-employee directors during the year ended
December 31, 2018 as computed in accordance with FASB ASC Topic 718. Assumptions used in computing the aggregate grant date fair value in accordance with FASB ASC Topic 718 are set forth in
Note 3 Share-Based Compensation to our audited financial statements included in the 2018 10-K.
The
following table indicates the grant date fair value for the annual option awarded to each non-employee director during the year ended December 31, 2018, as determined in
accordance with FASB ASC Topic 718, as well as the total number of shares subject to options outstanding as of December 31, 2018 for each non-employee director listed in the table above.
Assumptions used in computing the aggregate grant date fair value in accordance with FASB ASC Topic 718 are set forth in Note 3 Share-Based Compensation to our audited
financial statements included in the 2018 10-K.
|
|
|
|
|
|
|
|
Name
|
|
FASB ASC
Topic 718 Grant Date
Fair Value
($)
|
|
Total Shares Subject
to Options
Outstanding at
12/31/2018
(#)
|
|
J. R. Hyde, III
|
|
|
|
|
|
|
|
J. Kenneth Glass
|
|
|
99,197
|
|
|
46,500
|
|
Michael G. Carter, M.D.
|
|
|
99,197
|
|
|
46,500
|
|
Garry A. Neil, M.D.
|
|
|
99,197
|
|
|
28,750
|
|
Kenneth S. Robinson, M.D., M.Div.
|
|
|
99,197
|
|
|
46,500
|
|
Following
completion of the merger, it is expected that the combined organization will provide compensation to non-employee directors. Our current director compensation program will be
suspended at the time of the closing of the merger and the director compensation policies for the combined organization following the merger will be re-evaluated by the compensation committee and
board of directors of the combined organization following completion of the merger and may be subject to change. Non-employee directors of the combined organization are, however, expected to receive
annual cash retainers and equity compensation, although the amount of such compensation has not yet been determined.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Policies and Procedures for Review of Related Party Transactions
The GTx Board adopted a related party transactions policy, which specifies GTx's policies and procedures regarding transactions between GTx and
its employees, officers, directors or their family members. GTx's Chief Legal Officer is responsible for (a) ensuring that policy is distributed to all GTx officers, directors and other
managers and (b) requiring that any proposed related party transaction be presented to the Audit Committee for consideration before GTx enters into any such transactions. This policy can be
found on GTx's website (www.gtxinc.com) under "Investors" at "Corporate Governance."
27
Table of Contents
It
is the policy of GTx to prohibit all related party transactions unless the Audit Committee determines in advance of GTx entering into any such transaction that there is a compelling
business reason to enter into such a transaction. There is a general presumption that the Audit Committee will not approve a related party transaction with GTx. However, the Audit Committee may
approve a related party transaction if:
-
-
it finds that there is a compelling business reason to approve the transaction, taking into account such factors as the absence of other
unrelated parties to perform similar work for a similar price within a similar timeframe; and
-
-
it finds that it has been fully apprised of all significant conflicts that may exist or otherwise arise on account of the transaction, and it
believes, nonetheless, that GTx is warranted entering into the related party transaction and has developed an appropriate plan to manage the potential conflicts of interest.
Certain Transactions with or Involving Related Persons
Employment Arrangements.
For information on employment arrangements and compensation for service on the GTx Board, see "Executive
Compensation" and
"Director Compensation" under Item 11 of this report.
Warrant Exercises.
On November 14, 2014, we issued warrants, or the BVF Warrants, to Biotechnology Value Fund, L.P.,
Biotechnology
Value Fund II, L.P., Investment 10, L.L.C. and MSI BVF SPV, LLC, or collectively, the BVF Entities, to purchase an aggregate of 1,111,081 (whole) shares of our common stock (as adjusted
to give effect to the 2016 Reverse Stock Split) at an exercise price of $8.50 per share (as adjusted to give effect to the 2016 Reverse Stock Split) in connection with a private placement of our
common stock and warrants to purchase common stock. On March 13, 2018, the BVF Entities exercised the BVF Warrants in full pursuant to the "net exercise" provisions of the BVF Warrants
resulting in a net issuance on exercise to the BVF Entities of an aggregate of 674,579 shares of our common stock. Based solely on the difference between the fair market value of our common stock on
the date of exercise as determined pursuant to the net exercise provisions of the BVF Warrants and the exercise price of the BVF Warrants, the value realized by the BVF Entities upon exercise of the
BVF Warrants totaled approximately $14.6 million. Our involvement in the BVF Warrant exercises did not require approval under our related party transactions policy because our actions with
respect to such matters were undertaken in accordance with our pre-existing obligations under the BVF Warrants.
Loan Agreement.
On August 10, 2017, we entered into a loan agreement with J.R. Hyde, III and The Pyramid Peak Foundation to borrow
up to a
total of $15,000,000. Each of Mr. Hyde and The Pyramid Peak Foundation are significant stockholders, and Mr. Hyde serves on our board of directors. We did not borrow any amounts under
the loan agreement and the loan agreement terminated in accordance with its terms on September 29, 2017 in connection with the completion of the September 2017 private placement of our equity
securities described below.
28
Table of Contents
September 2017 Private Placement and Related Registration.
On September 29, 2017, we completed a private placement of an aggregate
of
5,483,320 immediately separable units, comprised of an aggregate of 5,483,320 shares of our common stock and warrants to purchase up to an aggregate of 3,289,988 additional shares of our common stock,
for an aggregate purchase price of approximately $48.5 million. The per unit purchase price for a share of common stock and a warrant to purchase 0.6 of a share of common stock was $8.845. The
warrants, which have a five-year term expiring on September 29, 2022, are immediately exercisable and have a per share exercise price of $9.02. Pursuant to the terms of the securities purchase
agreement, we filed a registration statement with the SEC in November 2017 to register the resale of the shares of our common stock and the shares of common stock underlying the warrants, and agreed
to keep one or more registration statements registering the shares effective until the earlier to occur of September 28, 2019 or the date on which all of the applicable shares of our common
stock have been sold or can be sold publicly without restriction or limitation under Rule 144 under the Securities Act. Our total expenses in connection with the filing of the November 2017
registration statement were approximately $70,000. The investors in the private placement included the following related parties:
|
|
|
|
|
|
|
|
|
|
|
Investor
|
|
Shares Purchased
|
|
Warrants Purchased
|
|
Aggregate Unit
Purchase Price
($)
|
|
J.R. Hyde III
(1)
|
|
|
1,130,582
|
|
|
678,349
|
|
|
9,999,997.79
|
|
The Pyramid Peak Foundation
(1)
|
|
|
565,291
|
|
|
339,174
|
|
|
4,999,998.90
|
|
Jack W. Schuler
(1)
|
|
|
226,116
|
|
|
135,669
|
|
|
1,999,996.02
|
|
Amzak Health Investors, LLC
(2)(3)
|
|
|
847,936
|
|
|
508,761
|
|
|
7,499,993.92
|
|
Aisling Capital IV LP
(2)
|
|
|
847,936
|
|
|
508,761
|
|
|
7,499,993.92
|
|
Boxer Capital, LLC
|
|
|
565,291
|
|
|
339,174
|
|
|
4,999,998.90
|
|
-
(1)
-
Executive
officer, director and/or greater than 5% stockholder (and a "related party") immediately prior to the private placement. Mr. Schuler is no longer a
stockholder of record of our capital stock.
-
(2)
-
Became
a greater than 5% stockholder of GTx as a result of the private placement and, accordingly, became a "related party" of GTx. Amzak Health
Investors, LLC and Aisling Capital IV LP are no longer stockholders of record of our capital stock.
-
(3)
-
Pursuant
to the terms of the securities purchase agreement, we reimbursed Amzak Health Investors for its legal fees in the amount of $33,078.
The
GTx Board of Directors appointed a Special Committee of the Board of Directors consisting of disinterested and independent directors to review and evaluate the private placement and
any other alternative transaction to the private placement, and delegated to the Special Committee the exclusive power and authority to consider, negotiate, disapprove or approve the private
placement, which the Special Committee ultimately determined to approve. Likewise, as a result of the participation of related parties in the private placement, the private placement was reviewed and
pre-approved by the Audit Committee in accordance with our related party transactions policy.
GTx has entered into indemnity agreements with each of its current directors and certain of its executive officers to give such directors and
officers additional contractual assurances regarding the scope of the indemnification set forth in GTx's charter and bylaws and to provide additional procedural protections.
29
Table of Contents
Director Independence
As required under the Nasdaq listing standards, a majority of the members of a listed company's Board of Directors must qualify as
"independent," as affirmatively determined by the Board of Directors. Consistent with the requirements of the SEC and Nasdaq, our Board of Directors reviews all relevant transactions or relationships
between each director, and GTx, its senior management and its independent registered public accounting firm. During this review, the Board considers whether there are any transactions or relationships
between directors or any member of their immediate family (or any entity of which a director or an immediate family member is an executive officer, general partner or significant equity holder) and
members of GTx's senior management or their affiliates.
As
a result of this review, the GTx Board affirmatively determined that the following five of our seven directors are independent members of the Board of Directors within the meaning of
the applicable Nasdaq listing standards: Dr. Carter, Mr. Hyde (Lead Director), Mr. Glass, Dr. Neil and Dr. Robinson. As a result of Mr. Hyde's significant
stock ownership in GTx, Mr. Hyde is not considered "independent" under applicable Nasdaq and SEC standards pertaining to membership of the Audit Committee (Mr. Hyde is not a member of
the Audit Committee). In determining that Mr. Hyde is an independent member of the Board of Directors within the meaning of the applicable Nasdaq listing standards, the GTx Board considered
Mr. Hyde's significant ownership interest in GTx, as well as his significant investments in our securities offerings in 2014, 2016 and 2017. Neither Mr. Hanover nor Dr. Wills is
"independent" within the meaning of the Nasdaq listing standards since each of Mr. Hanover and Dr. Wills serves as an executive officer of GTx.
The
Compensation Committee and the Nominating and Corporate Governance Committee of the Board are comprised entirely of directors who are independent within the meaning of the Nasdaq
listing standards, and the members of the Audit Committee are independent under applicable Nasdaq listing standards and SEC rules. In determining whether Dr. Carter, Mr. Hyde and
Mr. Glass are independent within the meaning of the Nasdaq listing standards pertaining to membership of the Compensation Committee, the GTx Board determined that, based on its consideration of
factors specifically relevant to determining whether any such director has a relationship to GTx that is material to that director's ability to be independent from management in connection with the
duties of a compensation committee member, no member of the Compensation Committee has a relationship that would impair that member's ability to make independent judgments about GTx's executive
compensation. In particular, the GTx Board considered, among other things, the source of each member's compensation, including compensation paid to such member by GTx, and also considered
Mr. Hyde's significant stock ownership in and status as an affiliate of GTx and determined that such compensation and affiliation, as applicable, would not impair the applicable member's
ability to make independent judgments about GTx's executive compensation. In the case of Mr. Hyde, the GTx Board determined that, as a significant stockholder, his interests are aligned with
other stockholders in seeking an appropriate executive compensation program for GTx.
30
Table of Contents